Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine for delirium prevention and sedative reduction in mechanically ventilated trauma ICU patients
IRCT20240319061337N1Phase 3Completed
- Sponsor
- Ilam University of Medical Sciences
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of olanzapine in delirium (2 arms), sponsored by Ilam University of Medical Sciences. Primary endpoints: Delirium severity based on MDAS, Average MDAS score over 3 days and 2 more. Started May 2024; status: completed.
02
Drugs
olanzapine
03
Conditions
delirium
Beyond the preview
Go deeper on IRCT20240319061337N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240319061337N1.